Olema Pharmaceuticals

OLMA

Market cap $1.18B

LOS ANGELES--(BUSINESS WIRE)--Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA.

Olema Pharmaceuticals Inc. (NASDAQ: OLMA) stock is trading lower on Monday, in reaction to data from Roche Holdings AG's (OTC: RHHBY) phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients.

SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 205,000 shares of the Company's common stock, effective as of March 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Guggenheim Securities Emerging Outlook: Biotech Summit Date and Time: February 11, 2026 at 10:00 a.m. ET Format: Fireside ChatLocation: New York, NY Citi's 2026 Virtual Oncology Leadership Summit Date and Time: February 19, 2026 at 1:00 p.m.

SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 24,000 shares of the Company's common stock, effective as of February 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Shane Kovacs, Chief Operating and Financial Officer, is departing the Company effective January 30, 2026 to pursue new opportunities. Mr. Kovacs will continue in a consulting capacity with Olema through August 1, 2026.

“Big mo” is an “eternal feature” of financial markets worldwide.

Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript